News | September 28, 2021
Bal Pharma ramps up API capacity of Gliclazide
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
The company does not expect the outcome of this inspection to impact its plans
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
Seed Spark is an online entrepreneurship program offered by Stanford Seed. Health Sensei emerged as a winner competing with 86 startups from their May-Aug 2021 graduating cohort
_256_384.jpg)
Terumo’s first product was the domestically produced, safe, high-quality thermometer. The company has since supported the healthcare ecosystem worldwide
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
Industry leaders to increase patient access to clinical research and scale remote enrollment of participants for trial sponsors to promote increased health equity
The recipient is a 57-year-old woman who was suffering from severe biventricular heart failure and had undergone cardiac surgery several years ago
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
Subscribe To Our Newsletter & Stay Updated
